promacta
(eltrombopag olamine)Novartis Pharmaceuticals Corporation
Usage: PROMACTA is indicated for treating thrombocytopenia in patients aged 1 year and older with persistent or chronic immune thrombocytopenia unresponsive to other treatments, chronic hepatitis C to facilitate interferon therapy, and severe aplastic anemia in conjunction with immunosuppressive therapy. It is not for myelodysplastic syndromes.